BioCentury
ARTICLE | Company News

EngMab, Celgene deal

October 10, 2016 7:00 AM UTC

Celgene acquired EngMab for $600 million. Celgene said the acquisition will help it pursue tumor necrosis factor receptor superfamily member 17 ( BCMA; TNFRSF17; CD269) as a target to treat multipl...